Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PDS Biotechnology Corp (PDSB)

PDS Biotech: NantWorks exercises warrants for 17,699,115 shares, $3.9 million gross proceeds

Neutral Impact 3 of 5 financing

PDS Biotechnology said NantWorks exercised outstanding common stock warrants at $0.22 per share, for 17,699,115 shares or pre-funded warrants in lieu of shares, bringing about $3.9 million in gross proceeds to the company. The warrants came from a September 2026 private placement that raised about $11.3 million gross, and the company plans to use the proceeds to support its lead program and general corporate purposes.

Key points

  • NantWorks exercised warrants for 17,699,115 shares at $0.22 per share, about $3.9 million in gross proceeds.
  • Warrants were issued in the private placement that initially closed on September 14, 2026, which raised about $11.3 million gross.
  • Exercise above the 19.9% beneficial ownership limit was taken as pre-funded warrants at $0.00033 per share, which do not expire.
  • Proceeds, with September 2026 placement net proceeds, will support PDS0301 toward a Phase 3 trial in metastatic colorectal cancer, the PDS0101 partnership strategy and general corporate purposes.

The filing

CompanyPDS Biotechnology Corp (PDSB)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:05 AM ET
Accession number0001140361-26-042898

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.